"Due to the widespread use of EGFR inhibitors for cancer treatment and the frequent occurrence of dermal toxicities, many patients do not receive optimal cancer therapy. This is often because the ...

CHICAGO – Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash compared ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth ...

LUT014 Gel Provides a Statistically Significant Benefit Over Placebo for the Treatment of Acneiform Rash Associated With Cetuximab or Panitumumab Therapy For Patients With Advanced Colorectal Cancer ...

EGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, ...

This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...